Table 1:
Baseline demographics of entire psoriasis cohort.
| Parameters | Psoriasis (N = 164) |
|---|---|
| Demographics and medical history | |
| Age, years | 50.0 ± 12.9 |
| Males | 91 (55%) |
| Ethnicity, Caucasians | 133 (81%) |
| Hypertension | 45 (27%) |
| Hyperlipidemia | 77 (47%) |
| Type 2 diabetes mellitus | 16 (10%) |
| Current tobacco use | 15 (9%) |
| Lipid treatment | 53 (32%) |
| Body mass index | 29.6 ± 6.1 |
| Waist-to-hip ratio | 0.95 (0.88 - 1.00) |
| Clinical and laboratory values | |
| Systolic blood pressure, mmHg | 123.6 ± 15.4 |
| Diastolic blood pressure, mmHg | 72.4 ± 10.2 |
| Total cholesterol, mg/dL | 181.5 ± 36.7 |
| HDL cholesterol, mg/dL | 55.7 ± 17.5 |
| LDL cholesterol, mg/dL | 101.2 ± 30.6 |
| Triglycerides, mg/dL | 121.8 ± 75.3 |
| Framingham risk score | 3.0 (1.0 – 6.0) |
| C-reactive protein, mg/L | 2.0 (0.8 - 4.4) |
| HOMA-IR* | 2.8 (1.7 – 4.7) |
| Cholesterol efflux capacity | 0.95 ± 0.15 |
| Psoriasis characterization | |
| Psoriasis area severity index score | 5.6 (3.0 – 9.6) |
| Total body surface area index | 4.1 (2.4 – 13.5) |
| Systemic or biologic treatment | 60 (37%) |
| Amygdalar activity (18FDG PET/CT) | |
| Amygdalar FDG uptake | 1.10 ± 0.11 |
| Aortic vascular inflammation (18FDG PET/CT) | |
| Target-to-background ratio | 1.71 ± 0.26 |
| Coronary plaque burdens (x100) | |
| Total burden, mm2 | 1.14 ± 0.45 |
| Non-calcified burden, mm2 | 1.10 ± 0.44 |
| Hematopoietic system activity (18FDG PET/CT) | |
| Bone marrow (SUV† max) | 3.93 ± 0.93 |
| Spleen (SUV† max) | 3.47 ± 0.75 |
Values reported in the table as Mean ± SD or Median (IQR) for continuous data and N (%) for categorical data.
*
HOMA-IR: Homeostasis model assessment of insulin resistance,
†
SUV: Standardized uptake value.